

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/915,543

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-70. (Cancelled).

Claim 71. (Currently Amended) An isolated polypeptide comprising:

(i) a peptide consisting of amino acids 177 to 204 of SEQ ID NO:15, wherein said peptide inhibits tcf-driven luciferase activity in colon cancer cells
~~or~~

(ii) a peptide having at least 90% amino acid sequence identity to said (i), wherein said peptide inhibits tcf-driven luciferase activity in colon cancer cells, or

(iii) a peptide consisting of amino acids 349 to 383 of SEQ ID NO:15, wherein said peptide inhibits tcf-driven luciferase activity in colon cancer cells
or

(iv) a peptide having at least 90% amino acid sequence identity to said (iii), wherein said peptide inhibits tcf-driven luciferase activity in colon cancer cells,

wherein said isolated polypeptide inhibits tcf-drive luciferase activity ~~blocks Lgs function in~~ colon cancer cells.

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/915,543

Claim 72. (Currently Amended) An isolated polypeptide comprising:

(i) a peptide consisting of amino acids 199 to 392 of SEQ ID NO:15, wherein said peptide inhibits tcf-driven luciferase activity in colon cancer cells,
or

(ii) a peptide having at least 90% amino acid sequence identity to (i), wherein said ~~isolated polypeptide blocks Lgs function~~ inhibits tcf-driven luciferase activity in colon cancer cells, or

(iii) a fragment of peptide (i) or (ii), wherein said fragment ~~comprises a binding site for~~ binds to an anti-Bcl9/hLgs antibody, and inhibits tcf-driven luciferase activity in colon cancer cells,

wherein said isolated polypeptide ~~blocks Lgs function~~ inhibits tcf-driven luciferase activity in colon cancer cells.

Claim 73. (Previously Presented) A chimeric molecule comprising the polypeptide of Claim 71 fused to a heterologous polypeptide.

Claim 74. (Previously Presented) A chimeric molecule comprising the polypeptide of Claim 72 fused to a heterologous polypeptide.

Claim 75. (Currently Amended) The chimeric molecule according to Claim ~~74~~73, wherein said heterologous polypeptide is selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 76. (Previously Presented) The chimeric molecule according to Claim 74, wherein said heterologous polypeptide is

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/915,543

selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 77. (Previously Presented) A pharmaceutical composition comprising the polypeptide of Claim 71, and a pharmaceutically acceptable carrier.

Claim 78. (Previously Presented) A pharmaceutical composition comprising the polypeptide of Claim 72, and a pharmaceutically acceptable carrier.